Clinical Trial: NCT01476787
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Celgene |
| Information Provided By: | Celgene |
| Last Update Posted: | 2025-05-14 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.
Official Title
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Conditions
Follicular Lymphoma
Intervention / Treatment
- Drug: Rituximab
- Drug: Lenalidomide
- Drug: Rituximab-CHOP
- Drug: Rituximab-CVP
- Drug: Rituximab-Bendamustine
Other Study ID Numbers
- RV-FOL-GELARC-0683C
- 2011-002792-42
Start Date (Actual)
2011-12-29
Primary Completion Date (Actual)
2024-04-30
Study Completion Date (Actual)
2024-04-30
Enrollment (Actual)
1030
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Celgene |
| Information Provided By: | Celgene |
| Last Update Posted: | 2025-05-14 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.
Official Title
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Conditions
Follicular Lymphoma
Intervention / Treatment
- Drug: Rituximab
- Drug: Lenalidomide
- Drug: Rituximab-CHOP
- Drug: Rituximab-CVP
- Drug: Rituximab-Bendamustine
Other Study ID Numbers
- RV-FOL-GELARC-0683C
- 2011-002792-42
Start Date (Actual)
2011-12-29
Primary Completion Date (Actual)
2024-04-30
Study Completion Date (Actual)
2024-04-30
Enrollment (Actual)
1030
Study Type
Interventional
Phase
Phase 3